IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance

Por White, Colin D., Li, Zhigang, Dillon, Deborah A., Sacks, David B.
Publicado em 2011

ICAM-1 as a molecular target for triple negative breast cancer

Por Guo, Peng, Huang, Jing, Wang, Liya, Jia, Di, Yang, Jiang, Dillon, Deborah A., Zurakowski, David, Mao, Hui, Moses, Marsha A., Auguste, Debra T.
Publicado em 2014

Trastuzumab for the Treatment of Salivary Duct Carcinoma

Por Limaye, Sewanti A., Posner, Marshall R., Krane, Jeffrey F., Fonfria, Maria, Lorch, Jochen H., Dillon, Deborah A., Shreenivas, Aditya V., Tishler, Roy B., Haddad, Robert I.
Publicado em 2013

In Vitro Liquid Extraction Surface Analysis Mass Spectrometry (ivLESA-MS) for Direct Metabolic Analysis of Adherent Cells in Culture

Por Basu, Sankha S., Randall, Elizabeth C., Regan, Michael S., Lopez, Begoña G.C., Clark, Amanda R., Schmitt, Nicholas D., Agar, Jeffrey N., Dillon, Deborah A., Agar, Nathalie Y. R.
Publicado no Anal Chem (2018)

Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma : A Search for the Early Precursors of Papi...

Por Fusco, Alfredo, Chiappetta, Gennaro, Hui, Pei, Garcia-Rostan, Ginesa, Golden, Lauren, Kinder, Barbara K., Dillon, Deborah A., Giuliano, Ada, Cirafici, Anna Maria, Santoro, Massimo, Rosai, Juan, Tallini, Giovanni
Publicado em 2002

Prevalence of germline TP53 mutations in HER2-positive Breast Cancer Patients

Por Rath, Michelle G., Masciari, Serena, Gelman, Rebecca, Miron, Alexander, Miron, Penelope, Foley, Kathleen, Richardson, Andrea L., Krop, Ian E., Verselis, Sigitas J., Dillon, Deborah A., Garber, Judy E.
Publicado no Breast Cancer Res Treat (2013)

Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade

Por Metzger‐Filho, Otto, Ferreira, Arlindo R., Jeselsohn, Rinath, Barry, William T., Dillon, Deborah A., Brock, Jane E., Vaz‐Luis, Ines, Hughes, Melissa E., Winer, Eric P., Lin, Nancy U.
Publicado no Oncologist (2018)

Neutralization of BCL-2/X(L) enhances the cytotoxicity of T-DM1 in vivo

Por Zoeller, Jason J., Vagodny, Aleksandr, Taneja, Krishan, Tan, Benjamin Y., O’Brien, Neil, Slamon, Dennis J., Sampath, Deepak, Leverson, Joel D., Bronson, Roderick T., Dillon, Deborah A., Brugge, Joan S.
Publicado no Mol Cancer Ther (2019)

Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways

Por Zervantonakis, Ioannis K., Poskus, Matthew D., Scott, Alexis L., Selfors, Laura M., Lin, Jia-Ren, Dillon, Deborah A., Pathania, Shailja, Sorger, Peter K., Mills, Gordon B., Brugge, Joan S.
Publicado no Proc Natl Acad Sci U S A (2020)

Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis

Por Calligaris, David, Caragacianu, Diana, Liu, Xiaohui, Norton, Isaiah, Thompson, Christopher J., Richardson, Andrea L., Golshan, Mehra, Easterling, Michael L., Santagata, Sandro, Dillon, Deborah A., Jolesz, Ferenc A., Agar, Nathalie Y. R.
Publicado em 2014

Breast Cancer Phenotype in Women with TP53 Germline Mutations: a Li Fraumeni Syndrome Consortium Effort

Por Masciari, Serena, Dillon, Deborah A., Rath, Michelle, Robson, Mark, Weitzel, Jeffrey N., Balmana, Judith, Gruber, Stephen B., Ford, James M., Euhus, David, Lebensohn, Alexandra, Telli, Melinda, Pochebit, Stephen M., Lypas, Georgios, Garber, Judy E
Publicado em 2012

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

Por Zoeller, Jason J., Vagodny, Aleksandr, Daniels, Veerle W., Taneja, Krishan, Tan, Benjamin Y., DeRose, Yoko S., Fujita, Maihi, Welm, Alana L., Letai, Anthony, Leverson, Joel D., Blot, Vincent, Bronson, Roderick T., Dillon, Deborah A., Brugge, Joan S.
Publicado no Breast Cancer Res (2020)

Phosphorylation of ETS1 by Src Family Kinases Prevents its Recognition by the COP1 Tumor Suppressor

Por Lu, Gang, Zhang, Qing, Huang, Ying, Song, Jiaxi, Tomaino, Ross, Ehrenberger, Tobias, Lim, Elgene, Liu, Wenbin, Bronson, Roderick T., Bowden, Michaela, Brock, Jane, Krop, Ian, Dillon, Deborah A., Gygi, Steven P., Mills, Gordon B., Richardson, Andrea L., Signoretti, Sabina, Yaffe, Michael B., Kaelin, William G.
Publicado em 2014

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers With CDK4/6 Inhibitors

Por Goel, Shom, Wang, Qi, Watt, April C., Tolaney, Sara M., Dillon, Deborah A., Li, Wei, Ramm, Susanne, Palmer, Adam C., Yuzugullu, Haluk, Varadan, Vinay, Tuck, David, Harris, Lyndsay N., Wong, Kwok-Kin, Liu, X. Shirley, Sicinski, Piotr, Winer, Eric P., Krop, Ian E., Zhao, Jean J.
Publicado no Cancer Cell (2016)

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer

Por Stover, Daniel G., Parsons, Heather A., Ha, Gavin, Freeman, Samuel S., Barry, William T., Guo, Hao, Choudhury, Atish D., Gydush, Gregory, Reed, Sarah C., Rhoades, Justin, Rotem, Denisse, Hughes, Melissa E., Dillon, Deborah A., Partridge, Ann H., Wagle, Nikhil, Krop, Ian E., Getz, Gad, Golub, Todd R., Love, J. Christopher, Winer, Eric P., Tolaney, Sara M., Lin, Nancy U., Adalsteinsson, Viktor A.
Publicado no J Clin Oncol (2018)

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Por Tolaney, Sara M., Guo, Hao, Pernas, Sonia, Barry, William T., Dillon, Deborah A., Ritterhouse, Lauren, Schneider, Bryan P., Shen, Fei, Fuhrman, Kit, Baltay, Michele, Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Mathew J., Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth, Partridge, Ann H., Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Publicado no J Clin Oncol (2019)

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

Por Mehta, Anita K., Cheney, Emily M., Hartl, Christina A., Pantelidou, Constantia, Oliwa, Madisson, Castrillon, Jessica A., Lin, Jia-Ren, Hurst, Katie E., de Oliveira Taveira, Mateus, Johnson, Nathan T., Oldham, William M., Kalocsay, Marian, Berberich, Matthew J., Boswell, Sarah A., Kothari, Aditi, Johnson, Shawn, Dillon, Deborah A., Lipschitz, Mikel, Rodig, Scott, Santagata, Sandro, Garber, Judy E., Tung, Nadine, Yélamos, José, Thaxton, Jessica E., Mittendorf, Elizabeth A., Sorger, Peter K., Shapiro, Geoffrey I., Guerriero, Jennifer L.
Publicado no Nat Cancer (2020)

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Por Hudeček, Jan, Voorwerk, Leonie, van Seijen, Maartje, Nederlof, Iris, de Maaker, Michiel, van den Berg, Jose, van de Vijver, Koen K., Sikorska, Karolina, Adams, Sylvia, Demaria, Sandra, Viale, Giuseppe, Nielsen, Torsten O., Badve, Sunil S., Michiels, Stefan, Symmans, William Fraser, Sotiriou, Christos, Rimm, David L., Hewitt, Stephen M., Denkert, Carsten, Loibl, Sibylle, Loi, Sherene, Bartlett, John M. S., Pruneri, Giancarlo, Dillon, Deborah A., Cheang, Maggie C. U., Tutt, Andrew, Hall, Jacqueline A., Kos, Zuzana, Salgado, Roberto, Kok, Marleen, Horlings, Hugo M.
Publicado no NPJ Breast Cancer (2020)

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials

Por Exman, Pedro, Garrido-Castro, Ana C., Hughes, Melissa E., Freedman, Rachel A., Li, Tianyu, Trippa, Lorenzo, Bychkovsky, Brittany L., Barroso-Sousa, Romualdo, Di Lascio, Simona, Mackichan, Colin, Lloyd, Max R., Krevalin, Max, Cerami, Ethan, Merrill, Margaret S., Santiago, Rebecca, Crowley, Lindsey, Kuhnly, Nicole, Files, Janet, Lindeman, Neal I., MacConaill, Laura E., Kumari, Priti, Tolaney, Sara M., Krop, Ian E., Bose, Ron, Johnson, Bruce E., Ma, Cynthia X., Dillon, Deborah A., Winer, Eric P., Wagle, Nikhil, Lin, Nancy U.
Publicado no JCO Precis Oncol (2019)

Genomic characterization of de novo metastatic breast cancer

Por Garrido-Castro, Ana C., Spurr, Liam F., Hughes, Melissa E., Li, Yvonne Y., Cherniack, Andrew D., Kumari, Priti, Lloyd, Maxwell R., Bychkovsky, Brittany, Barroso-Sousa, Romualdo, Lascio, Simona Di, Jain, Esha, Files, Janet, Mohammed-Abreu, Ayesha, Krevalin, Max, MacKichan, Colin, Barry, William T., Guo, Hao, Xia, Daniel, Cerami, Ethan, Rollins, Barrett J., MacConaill, Laura E., Lindeman, Neal I., Krop, Ian E., Johnson, Bruce E., Wagle, Nikhil, Winer, Eric P., Dillon, Deborah A., Lin, Nancy U.
Publicado no Clin Cancer Res (2020)